Suchergebnisse - "Chitsamatanga, Moses"

PubPharm (6)

1

Twice-Daily Dosing of Dolutegravir in Infants on Rifampicin Treatment : A Pharmacokinetic Substudy of the EMPIRICAL Trial

enthalten in: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 2024

von Jacobs, T. | Mumbiro, V. | Cassia, U. | +72

2

First-Line Antituberculosis Drug Concentrations in Infants With HIV and a History of Recent Admission With Severe Pneumonia

enthalten in: Journal of the Pediatric Infectious Diseases Society | 2023

von Chabala, C. | Jacobs, T. | Moraleda, C. | +73

3

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents : a secondary analysis of the ODYSSEY trial

enthalten in: The Lancet. Child & adolescent health | 2023

von Turkova, A. | White, E. | Kekitiinwa, A. | +127

4

Brief Report : Suboptimal Lopinavir Exposure in Infants on Rifampicin Treatment Receiving Double-dosed or Semisuperboosted Lopinavir/Ritonavir: Time for a Change

enthalten in: Journal of acquired immune deficiency syndromes (1999) | 2023

von Jacobs, T. | Mumbiro, V. | Chitsamatanga, M. | +48

5

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis : a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

enthalten in: The lancet. HIV | 2022

von Turkova, A. | Waalewijn, H. | Chan, M. | +121

CommentIn: Lancet HIV. 2022 Sep;9(9):e599-e600. - PMID 35868340

6

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks : results from the below 14 kg cohort in the randomised ODYSSEY trial

enthalten in: The lancet. HIV | 2022

von Amuge, P. | Lugemwa, A. | Wynne, B. | +127

1
[1]